Introduction
Payers in all countries are increasing their pressure on manufacturers to cut prices. But prescription drug pricing
and reimbursement policies vary markedly among the leading pharmaceutical markets, so, to best determine
pricing, pharmaceutical companies need to be aware of international price differentials. This report, featuring 33
data-rich tables and fi gures, provides comparisons of ex-manufacturer prices for 170 best-selling drugs in seven
major markets and by select therapeutic area.
Questions Answered in This Report
- In 2008, European prescription drug prices averaged just 61% of U.S. prices. How did prices vary among
the fi ve leading European markets? Which therapeutic areas had the highest and lowest prices relative
to U.S. prices?
- Japanese drug prices averaged 67% of U.S. prices in 2008. How many drugs were more expensive in Japan
than in the United States? What impact did the most recent biennial price revision have on drug prices
on Japan?
- The percentage price differential between the United States and other leading pharmaceutical markets is generally
much narrower for biologics than for small-molecule drugs. How do European and Japanese prices
for monoclonal antibodies compare with prices in the United States? How great is the percentage price
differential for recombinant proteins?
- Payers in all markets will be looking to increase pressure on manufacturers to moderate prescription drug
prices. How is the U.S. government's health reform agenda likely to impact drug prices in the United
States? What methods are European governments using to control pharmaceutical prices? What
changes to the Japanese pricing system are currently under discussion?
Scope
- Overall price differentials among markets: ex-manufacturer prices of 170 best-selling drugs in six
major markets (France, Germany, Italy, Spain, United Kingdom, Japan) relative to U.S. prices.
- Pricing hierarchy in individual markets: U.S. price of each of the 170 drugs under review as a
percentage of average prices in the six other markets under review; pricing hierarchy in individual
European markets, Japan, and the fi ve European markets overall as a percentage of U.S. prices.
- Price variations by therapeutic area: price variations among the 170 drugs in our analysis divided
into ten categories: cardiovascular, metabolic disease, immune and infl ammatory disease, infectious
disease, neurology, psychiatry, antineoplastic drugs, treatments for the side effects of chemotherapy,
gastrointestinal, and genitourinary.
- Prices of biologics: prices as a percentage of U.S. prices for 23 biologics (9 monoclonal antibodies
and 14 recombinant proteins) in the six other markets under study.
- Outlook and implications: implications of the new U.S. administration's health reform agenda for
drug prices in the United States; ongoing strict government control of drug prices in Europe; industry
calls for pricing reform in Japan.
Please note, the PDF e-mail from publisher version of this report is for a global site license.
|
